BMO Capital Markets affirmed their positive stance on Novo Nordisk (NYSE:NVO) stock, maintaining both their Outperform rating and a $105.00 price target. The endorsement comes in the wake of promising ...

By the time he was 5 ... Novo Nordisk. This may have been exciting to investors, but it wasn’t what any diabetes patient wanted to hear. Already Novo was under so much pressure to manufacture ...

Novo Nordisk said in a statement that up to 30% of people living with severe haemophilia A develop inhibitors, while for severe haemophilia B the rate is 5% to 10 ... portable pen that can be ...

In August, California-based Natron Energy selected the Kingsboro Business Park in Rocky Mount to build a massive $1.4 billion sodium-ion battery ... $4.5 billion in sales, and Novo Nordisk this ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

Novo Nordisk announced phase 1b/2a clinical trial results for amycretin this morning. Patients taking the GLP-1 drug lost an average of 9.7% of their weight in 36 weeks. This is the best news Novo ...

Novo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients ...

IMMvention and Novo Nordisk form a partnership to co-develop oral therapies for sickle cell disease, focusing on BACH1 ...

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

Finally, some good news for Novo Nordisk (NYSE: NVO) shareholders! Twice in the past two months, the Danish manufacturer of GLP-1 drugs for weight loss and diabetes treatment has reported clinical ...

On Friday, Novo Nordisk A/S NVO released topline results ... loss of 20.7% after 72 weeks compared to a reduction of 17.5% with semaglutide 2.4 mg and 2.4% with placebo. Price Action: NVO stock ...

Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the ...